COMMUNIQUÉS West-GlobeNewswire

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
05/08/2026
Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026 KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 [...]
Telix to Host R&D Day in New York City on September 22, 2026
05/08/2026
MELBOURNE, Australia and INDIANAPOLIS, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that it will host a Research and Development (R&D) Day on Tuesday [...]
Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy
05/08/2026
RMAT designation granted based on recent interim clinical data from ongoing Phase I/II clinical trial evaluating LX2020 for PKP2-ACM LX2020 now holds RMAT, Orphan Drug and Fast Track designations by the FDA NEW YORK, [...]
Shopify Delivers Big: 30%+ Growth Across GMV, Revenue, Gross Profit, and Free Cash Flow
05/08/2026
Internet, Everywhere, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Shopify (NASDAQ, TSX: SHOP) announced today financial results for the quarter ended June 30, 2026. Shopify achieved 34% revenue growth (33% in constant currency) [...]
Verano Announces Strong Second Quarter 2026 Financial Results Highlighted by $218 Million in Revenue
05/08/2026
Company delivers third consecutive quarter of revenue gains and improved cash flow from operations driven by organic growth CHICAGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO [...]
Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026
05/08/2026
Company to Host Conference Call at 8:30am ET REHOVOT, Israel, and HOBOKEN, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of [...]
Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences
05/08/2026
BERKELEY HEIGHTS, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biotechnology company, today announced that [...]
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
05/08/2026
BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral [...]
AC Immune First Half 2026 Financial and Corporate Update
05/08/2026
AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key advances across pipeline, [...]
Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026
05/08/2026
RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release [...]
Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update
05/08/2026
-- Reaffirms 2026 Guidance -- -- Multiple New Business Wins, Adding Impactful Programs to Pipeline -- -- Cost Reduction and Productivity Enhancements Continue to Strengthen Organization -- Conference Call Today at 8: [...]
Market launch of the nasal adrenaline spray, neffy®, for treatment of adults and children with severe allergies in Canada
05/08/2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced the market launch of neffy ® 2 mg in Canada following the approval by Health Canada in April 2026. The launch of this first ever nasal adrenaline spray for [...]
Applied Biologics Receives Central IRB Approval for Phase 3 BIOxHEAL™ Clinical Trial
05/08/2026
Clinical site activation and patient enrollment expected to begin in the coming weeks SCOTTSDALE, Ariz., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic [...]
Kane Biotech Announces Engagement of DNA Advisors
05/08/2026
DNA Advisors brings expertise in capital markets, strategic transactions, partnerships, and growth initiatives WINNIPEG, Manitoba, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane” or the “Company [...]
Bioventus Reports Second Quarter Financial Results
05/08/2026
Q2 reported revenue of $153.2 million increased 4% Q2 GAAP earnings of $0.47 per diluted share compared to the prior-year period earnings of $0.11 per diluted share Non-GAAP earnings* of $0.22 per diluted share compared [...]
Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
05/08/2026
WAYNE, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies [...]
Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
05/08/2026
- 17.3 month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib in combination with chemotherapy, reported in oral presentation at ASCO Annual Meeting on June 1 - - Phase 3 [...]
Medline Reports Second Quarter and First Six Months 2026 Results
05/08/2026
Second quarter net sales of $7.7 billion, an increase of 11.6% Second quarter net income of $139 million, a decrease of 58.3% Second quarter Adjusted EBITDA 1 of $1.1 billion, an increase of 13.4% First six months net [...]
BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer
05/08/2026
FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical study of Bria-PROS+ in prostate cancer Bria-PROS+ is BriaCell’s next generation personalized immunotherapy for [...]

Pages